Longitudinal Imaging Patterns and Corticosteroid Management in COVID-19 Patients with Pre-existing Interstitial Lung Disease: A 24-Month Cohort Analysis - Takeaways - MDSpire

Longitudinal Imaging Patterns and Corticosteroid Management in COVID-19 Patients with Pre-existing Interstitial Lung Disease: A 24-Month Cohort Analysis

  • By

  • Cheng Jiang

  • Sihao Cui

  • Shixuan Hou

  • Min Chen

  • Qiuyan Huang

  • Xiangyu Zhang

  • Sijia Li

  • Deqin Yang

  • Mengshu Cao

  • February 10, 2026

  • 0 min

Share

  • 1

    Patients with pre-existing interstitial lung disease (ILD) face significantly higher risks of ICU admission and mortality during COVID-19.

  • 2

    SARS-CoV-2 infection may exacerbate ILD and lead to progressive fibrotic remodeling rather than merely causing transient inflammation.

  • 3

    Longitudinal imaging studies are needed to understand the long-term structural consequences of COVID-19 on ILD patients.

  • 4

    Corticosteroids are crucial for managing ILD exacerbations, but optimal dosing and tapering strategies post-COVID-19 remain unclear.

  • 5

    This study aims to analyze clinical outcomes and HRCT changes in COVID-19 patients with ILD over 24 months, focusing on corticosteroid effects.

Original Source(s)

Longitudinal Imaging Patterns and Corticosteroid Management in COVID-19 Patients with Pre-existing Interstitial Lung Disease: A 24-Month Cohort Analysis

  • by Cheng Jiang, Sihao Cui, Shixuan Hou, Min Chen, Qiuyan Huang, Xiangyu Zhang, Sijia Li, Deqin Yang, Mengshu Cao

  • February 10, 2026

Related Content

Cough Audio Recognition for Early Detection of Respiratory Diseases: Algorithm Development and Validation Study

MDA5-related juvenile dermatomyositis and interstitial lung disease: Transitioning from rapid progression to a quiescent state in three pediatric cases from South Africa, along with a literature review.

Downstream Healthcare Use Associated with Primary Care In-Person and Telemedicine Visits in 2022